Germany, FranceGermany

Sartorius Stedim Biotech rocks single-use bioreactor market

14.05.2009

Aubagne/Frankfurt – Sartorius Stedim Biotech SA has substantially expanded its technology portfolio as a supplier for the bio-pharmaceutical industry. At the ACHEMA, the world´s largest trade fair for bioprocess equipment, the company presented two new prototypes of single-use bioreactors that make use of novel mixing technologies co-developed with Bayer Technology Services GmbH (BTS) and Swiss ExcellGene SA. The disposable systems are a major driver of growth for suppliers of the biopharmaceutical industry, because they offer cheaper and more flexible production possibilties than stainless steel fermentors that need time-consuming and expensive cleaning validation.
With the new bioreactors, which are specially designed for the manufacture of monoclonal antibodies, recombinant proteins and vaccines, Sartorius attacks competitors like Thermo Fisher, who offer single use stirred bioreactors or GE Healthcare, who markets shaked reusable plastic bags for mid-scale biomanufacture.
„Based on this comprehensive technology platform, we are taking a huge step forward towards achieving our goal of becoming the global market leader in single-use bioreactors," said Dr. Oscar-Werner Reif, Member of Sartorius Stedim Biotech's Board of Directors.
From 2010, the company plans to extend its technology portfolio, which already comprises stirred and shaked bioreactor types, by the novel systems. The rotationally oscillating bioreactor, co-developed with Bayer Schering Pharma AG, allows for surface or membrane gasing of sensitive cultures. The orbital shake bioreactor, developed with ExcellGene, allows for screening of media and cultivation conditions. Each of the four agitation technologies offers user specific advantages contingent upon the cells to be produced, the scale-up level of the cell cultures and additional process parameters. Despite financial crisis, ACHEMA achieved its second best result ever, regarding the number of exhibitors.

GermanyGermany

27.10.2011

Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

GermanyGermany

24.10.2011

Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...

GermanyGermany

14.10.2011

Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...

GermanyGermany

11.10.2011

Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...

GermanyGermany

01.10.2011

Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...

GermanyGermany

27.09.2011

Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...

GermanyGermany

22.09.2011

Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...

GermanyGermany

08.09.2011

Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....

GermanyGermany

06.09.2011

Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/2/article/sartorius-stedim-biotech-rocks-single-use-bioreactor-market.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%
  • ADDEX3.32 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%

TOP

  • SANTHERA94.75 CHF47.8%
  • FORMYCON8.30 EUR19.9%
  • EPIGENOMICS3.61 EUR14.6%

FLOP

  • EVOTEC3.12 EUR-16.8%
  • MEDIGENE3.98 EUR-15.7%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA94.75 CHF2524.7%
  • CO.DON2.71 EUR218.8%
  • PAION2.71 EUR155.7%

FLOP

  • CYTOS0.25 CHF-93.7%
  • 4SC1.16 EUR-40.5%
  • MERCK KGAA68.05 EUR-38.7%

No liability assumed, Date: 14.09.2014


Current issue

All issues

Product of the week

Products